Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

Am J Hematol. 2019 Jun;94(6):E150-E153. doi: 10.1002/ajh.25447. Epub 2019 Mar 6.

Authors

Paolo Strati¹, Seung Tae Lee¹, Purnima Teegavarupu¹, Anusha Karri¹, Saswatha Anireddy¹, Fredrick B Hagemeister¹, Jorge Romaguera¹, Luis E Fayad¹, Maria A Rodriguez¹, Felipe Samaniego¹, Nathan Fowler¹, Jason Westin¹, Michael Wang¹, Hun Ju Lee¹, Chelsea Pinnix², Jillian R Gunther², Bouthaina Dabaja², Lei Feng³, Richard Eric Davis¹, Sattva S Neelapu¹

Affiliations

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

PMID: 30785215
DOI: 10.1002/ajh.25447

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adult
Aged
Anti-Bacterial Agents / administration & dosage*
Disease-Free Survival
Female
Follow-Up Studies
Helicobacter pylori*
Humans
Lymphoma, B-Cell, Marginal Zone / drug therapy*
Lymphoma, B-Cell, Marginal Zone / mortality*
Male
Middle Aged
Retrospective Studies
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / mortality*
Survival Rate

Substances

Anti-Bacterial Agents